Pediatric Asthma Clinical Trials 2023

What are the top hospitals conducting pediatric asthma research?

When it comes to advancing the understanding and treatment of pediatric asthma, several hospitals have emerged as leaders in conducting clinical trials. In Saint Louis, a prominent research site is currently undertaking six active trials dedicated to pediatric asthma. Over time, they have contributed to 32 studies that focus on this condition, with their first recorded trial dating back to 2010. Similarly, in Newport Beach, another research site has been making significant strides by conducting five ongoing clinical trials for pediatric asthma. With a cumulative total of 21 completed studies since their inaugural trial in 2011, they are committed to improving the lives of young patients living with this respiratory disease.

In Orlando's GSK Investigational Site, researchers are engaged in five active pediatric asthma trials as part of their mission to enhance knowledge and treatments for this condition. Their dedication extends beyond recent efforts; they hold a history of contributing to 14 previous investigations starting from an initial pediatric asthma trial conducted in 2001.

Meanwhile Oklahoma City’s Research Site also plays an essential role by conducting five current clinical tests aimed towards alleviating symptoms associated with pediatric asthma while having made substantial contributions through forty-two earlier trials since initiating its pioneering investigation into the field back in2006.Similarly at San Antonio's Research Site where likewise there are aroundfive ongoingpediatric asthmaclinical inquiries.These includeforty-fivetrials previously undertaken overthe past fifteen years sincethe first ever-trial wasrecordedin2006

These remarkable hospitals across different locations demonstrate unwavering commitment when it comes tounderstanding and addressingpediatricasthma.Asthma affectsmillions offamilies worldwide,and these institutions serve assymbolsof hope andprogressionby providingopportunitiesfor childrenandtheir families toparticipate inclinicaltrialsthatleadtoimprovedtreatmentsand ultimatelyenhancethe qualityoflife forthose affected

Which are the best cities for pediatric asthma clinical trials?

When it comes to pediatric asthma clinical trials, several cities stand out as leaders in research and development. Miami, Florida leads the way with 24 active trials exploring treatments such as 75 mg BID, Dupilumab, and RPT193 400 mg. New york follows closely behind with 18 ongoing studies focused on innovative approaches like Controlling Asthma Program for Adolescents (CAMP Air) and GSK3511294 (Depemokimab). Saint Louis, Missouri also shows promise with 16 active trials examining options like Tezepelumab and Asthma reliever therapies. These cities offer valuable opportunities for children suffering from asthma to participate in cutting-edge clinical trials that may lead to improved management of their condition.

Which are the top treatments for pediatric asthma being explored in clinical trials?

Ongoing clinical trials are shedding light on the top treatments under investigation for pediatric asthma. Among these potential breakthroughs, dupilumab stands out with its involvement in five active trials and a total of 18 pediatric asthma trials since its introduction in 2011. Equally promising is tezepelumab, also being explored in five ongoing trials and showing promise with 13 all-time pediatric asthma trials. Additionally, the community health navigator program has caught attention with three active studies focused on improving outcomes for young asthma patients—an innovative approach introduced just this year. Lastly, GSK3511294 (Depemokimab) joins the ranks as an investigational treatment currently involved in three active clinical trials aimed at advancing our understanding and management of pediatric asthma. These ongoing efforts offer hope for improved care and quality of life for children living with this challenging condition.

What are the most recent clinical trials for pediatric asthma?

Exciting developments are underway in the realm of pediatric asthma research, with recent clinical trials offering new insights and potential treatments. One notable trial is exploring the efficacy of TEV-56248 Low Dose for pediatric asthma, aiming to provide a safe and effective treatment option for young patients. Additionally, Tezepelumab has shown promise as a potential therapy for children suffering from this condition. Another trial focuses on RPT193 400 mg, evaluating its effectiveness in managing symptoms among children with asthma. These studies shed light on innovative approaches that may significantly improve the lives of pediatric asthma patients going forward.

What pediatric asthma clinical trials were recently completed?

Several recent clinical trials have made significant strides in advancing the treatment of pediatric asthma. In April 2022, Cipla Ltd. completed a trial investigating the effectiveness of Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg on young patients with asthma. Notably, AVTX-002, sponsored by Cerecor Inc., achieved completion in February 2022 and showed promising results for potential therapeutic interventions. Additionally, Dupilumab trials conducted by the University of Michigan were successfully concluded in the same month, further expanding our understanding of effective treatments for pediatric asthma. These advancements underscore ongoing efforts to enhance care for children grappling with this respiratory condition.